Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 381 results for lung cancer

  1. Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]

    In development Reference number: GID-TA10225 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (MIB194)

    NICE has developed a medtech innovation briefing (MIB) on superDimension Navigation System to help diagnostic sampling of peripheral lung lesions .

    Medtech innovation briefing
    Published
    11 October 2019

  3. Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]

    Awaiting development Reference number: GID-TA11755 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses (HTG163)

    Evidence-based recommendations on endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses. This involves inserting a thin tube through the mouth into the lungs to take samples for examination.

    HealthTech guidance
    Published
    27 February 2008
    View recommendations

    Sections for HTG163

  5. Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.

    Technology appraisal guidance
    Published
    17 August 2022
    View recommendations

    Sections for TA818

  6. Evidence on the safety of microwave ablation for treating primary lung cancer and metastases in the lung is adequate but shows it can cause infrequent serious complications. Evidence on its efficacy shows it reduces tumour size. But the evidence on improvement in survival, long-term outcomes and quality of life is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page. Further research should be randomised controlled trials or disease registry studies. It should report patient selection, disease progression and quality of life, and take account of the effectiveness of managing oligometastatic disease in patients.

    on the safety of microwave ablation for treating primary lung cancer and metastases in the lung is adequate but shows it...

    Research recommendation
    Published
    24 March 2022

  7. Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]

    In development Reference number: GID-TA10248 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]

    Awaiting development Reference number: GID-TA11497 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

    Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.

    Technology appraisal guidance
    Published
    17 October 2018
    View recommendations

    Sections for TA544

  10. Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]

    Awaiting development Reference number: GID-TA11706 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Irreversible electroporation for treating renal cancer (HTG303)

    Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.

    HealthTech guidance
    Published
    23 February 2013
    View recommendations

    Sections for HTG303

  12. Cryotherapy for malignant endobronchial obstruction (HTG89)

    Evidence-based recommendations on cryotherapy for malignant endobronchial obstruction. This involves using cold temperatures to destroy the cancer tissue that’s causing a blockage.

    HealthTech guidance
    Published
    23 November 2005
    View recommendations

    Sections for HTG89

  13. Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

    Awaiting development Reference number: GID-TA11094 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Selective internal radiation therapy for primary hepatocellular carcinoma (HTG314)

    Evidence-based recommendations on selective internal radiation therapy (SIRT) for primary hepatocellular carcinoma. This involves infusion of microspheres loaded with yttrium-90, which aims to deliver radiation directly into the tumour, minimising the risk of radiation damage to healthy surrounding tissues.

    HealthTech guidance
    Published
    23 July 2013
    View recommendations

    Sections for HTG314

  15. Irreversible electroporation for treating liver metastases (HTG304)

    Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.

    HealthTech guidance
    Published
    23 February 2013
    View recommendations

    Sections for HTG304